PD-1/PD-L1-IN 3|CAS 1629654-95-0|DC Chemicals

Cas No.:	1629654-95-0
Chemical Name:	PD-1/PD-L1-IN 3
Synonyms:	Maa-FANPHL-Sar-WSW-Nle-Nle-RCG (Disulfide bridge: Maa1-Cys15)
SMILES:	O=C(N([C@H](C(N([C@H](C(N[C@H](C(N[C@](CSCC(N[C@H](C(N([C@H](C(N[C@H](C(N1CCC[C@]1(C(N[C@]([H])(C(N[C@H](C(N(CC(N[C@H](C(N[C@H](C2=O)CO)=O)CC3=CNC4=CC=CC=C34)=O)C)=O)CC(C)C)=O)CC5=CN=CN5)=O)[H])=O)CC(N)=O)=O)C)C)=O)CC6=CC=CC=C6)=O)([H])C(NCC(N)=O)=O)=O)CC
Formula:	C₈₉H₁₂₆N₂₄O₁₈S
M.Wt:	1852.17
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:	[1] MILLER Michael Matthew, et al. Patent, Pub. No.:WO/2014/151634

MSDS

COA

Cat. No.	Product name	Field of application
DC49130	PD-1/PD-L1-IN-23	PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester prodrug of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice.
DC44154	PD-1/PD-L1-IN 3	PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases.
DC42714	BMS-8	BMS-8 inhibits the PD-1/PD-L1 interaction with IC50 of 7.2 μM. BMS-8, binds directly to PD-L1 and induces formation of PD-L1 homodimers, which in turn prevents the interaction with PD-1[1].
DC12058	BMS-1166 (PD-1/PD-L1-IN1)	BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor with an IC50 of 1.4 nM.